Syndax Pharmaceuticals SNDX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$285.42M+10.5% | -$318.76M-52.3% | -$209.36M-40.2% | -$149.34M-699% | ||
| $47.5M+10.4% | $43.03M+39.0% | $30.95M+93.2% | $16.02M+20.3% | ||
| -$322.98M-17.5% | -$274.9M-71.2% | -$160.6M-20.1% | -$133.68M-559% | ||
| $290.04M— | —— | —— | -$186.19M— | ||
| $13.68M-96.1% | $353.37M+33.8% | $264.13M+42.2% | $185.78M+56.8% | ||
| —— | —— | $223.87M+249% | -$150.59M— | ||
| -$323.17M-17.6% | -$274.9M-71.2% | -$160.6M-20.1% | -$133.68M-561% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Syndax Pharmaceuticals generate?
- Syndax Pharmaceuticals (SNDX) generated -$278.2M in operating cash flow over the trailing twelve months.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
